Tag: antibody lecanemab

FDA, News, Regulations

Eisai/Biogen could get FDA verdict on new Alzheimer’s drug by 6 Jan

July 6, 2022

Via: Pharmaphorum

The US regulator has been reviewing lecanemab as a treatment for patients with early-stage Alzheimer’s and amyloid plaques in the brain under a rolling biologics license application which completed in May. The timeline puts lecanemab ahead of Lilly’s donanemab in […]